Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Ono Pharmaceutical Co., Ltd.
  6. Summary
    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD.

(4528)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
2446 2414 2416 2425 2461.5 Last
784100 888400 817800 809300 766900 Volume
+0.85% -1.31% +0.08% +0.37% +1.51% Change
Estimated financial data (e)
Sales 2022 349 B 3 056 M 3 056 M
Net income 2022 84 105 M 736 M 736 M
Net cash position 2022 101 B 883 M 883 M
P/E ratio 2022 14,6x
Yield 2022 2,23%
Sales 2023 395 B 3 461 M 3 461 M
Net income 2023 101 B 886 M 886 M
Net cash position 2023 143 B 1 254 M 1 254 M
P/E ratio 2023 12,2x
Yield 2023 2,55%
Capitalization 1 229 B 10 762 M 10 753 M
EV / Sales 2022 3,23x
EV / Sales 2023 2,74x
Nbr of Employees 3 607
Free-Float 77,2%
More Financials
Company
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals. 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Ratings of Ono Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ONO PHARMACEUTICAL CO., LTD.
10/14Caris Life Sciences and Ono Pharmaceutical Announces Strategic Collaboration Leveraging..
CI
09/29ONO PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
08/26Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabo..
AQ
08/25EXELIXIS : Partner Takeda Secures Cabometyx Combo Nod in Japan for Metastatic Renal Cell C..
MT
07/30ONO PHARMACEUTICAL : Corporate Governance Report
PU
07/30Ono Pharmaceutical Co., Ltd. Provides Earnings Forecast for the Year 2021
CI
07/30Ono Pharmaceutical Co., Ltd. Plan to Pay an Interim and Year-End Dividend
CI
06/09Japanese shares rise, Eisai drops after 2 days of limit-up gains
RE
06/02Japan shares rally as reopening hopes boosts travel, real estate firms
RE
06/01Japan shares rally as reopening hopes boosts travel, real estate firms
RE
05/24Rehab for JAPAN Co., Ltd. announced that it has received ą700 million in funding from a..
CI
04/28ONO PHARMACEUTICAL : Announcement of New Office Establishment of U.S. Subsidiary (ONO PHAR..
AQ
04/22ONO PHARMACEUTICAL : Helsinn Announces the Launch of Adlumiz (anamorelin) for the Treatmen..
AQ
04/21PRESS RELEASE : Helsinn Announces the Launch of Adlumiz(R) (anamorelin) for the Treatment ..
DJ
04/15ONO PHARMACEUTICAL : Submits Supplemental Application for Approval for Opdivo (Nivolumab) ..
AQ
More news
News in other languages on ONO PHARMACEUTICAL CO., LTD.
06/02Nikkei 225 : Borsa Tokyo chiude in rialzo, speranze riapertura spingono titoli turismo,..
2020Borsa Tokyo riparte dopo stop tecnico, Nikkei in calo su notizia Trump positivo a Covid
2019DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 18.07.2019 - 15.15 Uhr
2019Bayer hofft auf neues Einsatzfeld für Krebsmedikament Stivarga
2018TOKYO STOCK EXCHANGE : Tokyo finit en hausse de 0,10%
More news
Chart ONO PHARMACEUTICAL CO., LTD.
Duration : Period :
Ono Pharmaceutical Co., Ltd. Technical Analysis Chart | 4528 | JP3197600004 | MarketScreener
Technical analysis trends ONO PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 2 461,50 JPY
Average target price 3 150,00 JPY
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Gyo Sagara President & Representative Director
Toichi Takino Managing Executive Officer & GM-Research
Yutaka Kato Independent Outside Director
Masao Nomura Independent Outside Director
Shusaku Nagae Independent Outside Director